Find, compare & contact
Eslicarbazepine
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Eslicarbazepine API 104746-04-5?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Eslicarbazepine. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Eslicarbazepine
- Synonyms:
- Eslicarbazepina , S(+)-Liscarbazepine
- Cas Number:
- 104746-04-5
- DrugBank number:
- DB14575
- Unique Ingredient Identifier:
- S5VXA428R4
General Description:
Eslicarbazepine, identified by CAS number 104746-04-5, is a notable compound with significant therapeutic applications. Eslicarbazepine is an anti-epileptic medication available commercially as .
Mechanism of Action:
Eslicarbazepine functions by: The precise mechanism(s) by which eslicarbazepine exerts anticonvulsant activity is unknown but is thought to involve inhibition of voltage-gated sodium channels. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Eslicarbazepine belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom, classified under the direct parent group Dibenzazepines. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Benzazepines class, specifically within the Dibenzazepines subclass.
Categories:
Eslicarbazepine is categorized under the following therapeutic classes: Anticonvulsants, Carboxamide Derivatives, Cardiovascular Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C19 inhibitors (strength unknown), Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers, Cytochrome P-450 CYP3A4 Inducers (strength unknown), Cytochrome P-450 Enzyme Inducers, Cytochrome P-450 Enzyme Inhibitors, Eslicarbazepine and prodrugs, Heterocyclic Compounds, Fused-Ring, Membrane Transport Modulators, Nervous System, Sodium Channel Blockers, UGT1A1 Substrates, Voltage-Gated Sodium Channel Blockers. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Eslicarbazepine is a type of Anticonvulsants
Anticonvulsants are a vital category of pharmaceutical Active Pharmaceutical Ingredients (APIs) used for the treatment of seizures and epilepsy. These APIs play a crucial role in managing and preventing convulsions, which are characterized by abnormal electrical activity in the brain. With a significant demand for effective anticonvulsant medications, these APIs hold immense importance in the pharmaceutical industry.
Anticonvulsant APIs work by stabilizing the excessive electrical activity in the brain, preventing or reducing seizures. They achieve this by targeting specific receptors or channels involved in the regulation of neuronal excitability. Some commonly used anticonvulsant APIs include phenytoin, valproic acid, carbamazepine, and lamotrigine.
Pharmaceutical companies utilize these APIs to formulate various dosage forms, such as tablets, capsules, and oral suspensions, ensuring convenient administration for patients. Additionally, anticonvulsant APIs may also be employed in the development of extended-release formulations, providing sustained and controlled drug release.
The market for anticonvulsant APIs continues to grow due to the rising prevalence of epilepsy and other seizure disorders. Moreover, ongoing research and development efforts aim to enhance the efficacy, safety, and tolerability of these APIs, ensuring better treatment outcomes for patients.
In conclusion, anticonvulsant APIs are a crucial pharmaceutical category used to manage seizures and epilepsy. With their ability to stabilize brain activity, these APIs play a pivotal role in improving the quality of life for individuals living with these conditions. The pharmaceutical industry's continued focus on research and development in this area ensures the availability of advanced and effective anticonvulsant medications for patients in need.
